Featured Research

from universities, journals, and other organizations

Rare skin cancer vaccine: Early stage research begins

Date:
November 5, 2010
Source:
Yorkshire Cancer Research
Summary:
Scientists plan to introduce the genetic material of a virus into normal human skin cells to produce skin cells that have features of Merkel cell carcinoma cancers. They will use these synthetic MCC cancer cells along with real MCC cell patient samples to analyze the reactions of human immune cells against them. The scientists ultimately hope to increase current knowledge about the human body’s ability to eliminate MCC cancer cells to help develop a vaccine in the future.

Leeds-based scientists, funded by Yorkshire Cancer Research headquartered in Harrogate, North Yorkshire, plan to introduce the genetic material of a virus into normal human skin cells to produce skin cells that have features of Merkel Cell Carcinoma cancers.

Researchers at the University of Leeds have taken their first steps towards understanding why a rare skin cancer that is rapidly growing in incidence in Europe and the USA is not recognised by the body's immune system.

Merkel cell carcinoma (MCC) arises from uncontrolled growth of skin cells and usually develops on sun-exposed areas as a firm, painless, red-coloured bump that grows over several weeks to months.

The condition typically develops in people aged 65 and over and those with weakened immune systems and there are currently around 1500 cases a year in the UK with one third of these proving fatal.

During recent research, around 80 percent of MCCs on human skin were shown to contain a virus termed Merkel cell polyomavirus which is believed to be associated with the growth of this cancer.

Now Leeds-based scientists, funded by Yorkshire Cancer Research headquartered in Harrogate, North Yorkshire, plan to introduce the genetic material of this virus into normal human skin cells to produce skin cells that have features of MCC cancers.

They will use these synthetic MCC cancer cells along with real MCC cell patient samples to analyse the reactions of human immune cells against them.

The scientists ultimately hope to increase current knowledge about the human body's ability to eliminate MCC cancer cells to help develop a vaccine in the future.

Professor Eric Blair, who is leading the project, said: "Since a virus is involved in the development of Merkel cell carcinoma skin cancer it is important to understand how the virus prevents the immune system attacking the MCC tumour.

"We are aiming to develop strategies to prevent or eradicate tumours and improve the prognosis of patients who suffer with this terrible skin disease which is currently extremely poor."


Story Source:

The above story is based on materials provided by Yorkshire Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

Yorkshire Cancer Research. "Rare skin cancer vaccine: Early stage research begins." ScienceDaily. ScienceDaily, 5 November 2010. <www.sciencedaily.com/releases/2010/11/101105085423.htm>.
Yorkshire Cancer Research. (2010, November 5). Rare skin cancer vaccine: Early stage research begins. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2010/11/101105085423.htm
Yorkshire Cancer Research. "Rare skin cancer vaccine: Early stage research begins." ScienceDaily. www.sciencedaily.com/releases/2010/11/101105085423.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins